191 related articles for article (PubMed ID: 32147352)
21. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
[TBL] [Abstract][Full Text] [Related]
22. Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau).
Prause LW; Manka L; Millan C; Lang E; Wyler SF; Grobholz R; Hammerer-Lercher A; Sulser T; Recker F; Kwiatkowski M; Eberli D
World J Urol; 2020 Oct; 38(10):2485-2491. PubMed ID: 31865534
[TBL] [Abstract][Full Text] [Related]
23. The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam.
Remmers S; Nieboer D; Roobol MJ;
Eur Urol Open Sci; 2023 May; 51():1-6. PubMed ID: 37187725
[TBL] [Abstract][Full Text] [Related]
24. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Määttänen L; Lilja H; Denis LJ; Recker F; Paez A; Bangma CH; Carlsson S; Puliti D; Villers A; Rebillard X; Hakama M; Stenman UH; Kujala P; Taari K; Aus G; Huber A; van der Kwast TH; van Schaik RH; de Koning HJ; Moss SM; Auvinen A;
Lancet; 2014 Dec; 384(9959):2027-35. PubMed ID: 25108889
[TBL] [Abstract][Full Text] [Related]
25. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
[TBL] [Abstract][Full Text] [Related]
26. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
[TBL] [Abstract][Full Text] [Related]
27. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
28. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Remmers S; Bangma CH; Godtman RA; Carlsson SV; Auvinen A; Tammela TLJ; Denis LJ; Nelen V; Villers A; Rebillard X; Kwiatkowski M; Recker F; Wyler S; Zappa M; Puliti D; Gorini G; Paez A; Lujan M; Nieboer D; Schröder FH; Roobol MJ
Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
[TBL] [Abstract][Full Text] [Related]
29. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.
Pinsky PF; Miller E; Prorok P; Grubb R; Crawford ED; Andriole G
BJU Int; 2019 May; 123(5):854-860. PubMed ID: 30288918
[TBL] [Abstract][Full Text] [Related]
30. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciatto S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
J Med Screen; 2013 Mar; 20(1):33-38. PubMed ID: 28075228
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer screening: and yet it moves!
Kwiatkowski M; Randazzo M; Kluth L; Manka L; Huber A; Recker F
Asian J Androl; 2015; 17(3):437-8. PubMed ID: 25532573
[TBL] [Abstract][Full Text] [Related]
32. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; van der Cruijsen IW; Liem MK; Korfage IJ; Lous JJ; Schröder FH; de Koning HJ
Int J Cancer; 2003 Jun; 105(3):394-9. PubMed ID: 12704675
[TBL] [Abstract][Full Text] [Related]
33. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
34. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
35. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
37. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
[TBL] [Abstract][Full Text] [Related]
38. A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality.
Zappa M; Puliti D; Hugosson J; Schröder FH; van Leeuwen PJ; Kranse R; Auvinen A; Carlsson S; Kwiatkowski M; Nelen V; Paez Borda A; Roobol MJ; Villers A
Eur Urol; 2014 Sep; 66(3):401-3. PubMed ID: 24412230
[TBL] [Abstract][Full Text] [Related]
39. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
